MC
PACB icon

Moors & Cabot’s Pacific Biosciences PACB Stock Holding History

Moors & Cabot’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,000
Closed -$111K – 860
2022
Q2 		$111K Buy
+25,000
New +$152K 0.01% 746

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moors & Cabot's PACB Position: Q3 2022 in Review

Moors & Cabot sold out of Pacific Biosciences (PACB) in Q3 2022, closing a stake of 25,000 shares — an estimated $111K sold.

Moors & Cabot first reported a position in PACB in Q2 2022 and held it in 1 quarter. The position peaked at $111K in Q2 2022. 227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

  • Moors & Cabot reported no remaining Pacific Biosciences position as of Q3 2022 after selling out during the quarter.
  • Moors & Cabot sold 25,000 Pacific Biosciences shares in Q3 2022, an estimated $111K.
  • Moors & Cabot first reported a position in Pacific Biosciences in Q2 2022 and held it in 1 quarter.
  • Moors & Cabot's Pacific Biosciences position peaked at $111K in Q2 2022.
  • 227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Moors & Cabot's 13F filing for Q3 2022, filed 8 Nov 2022.